Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

161. HIV

contact us via jon.brassey@tripdatabase.com Top results for hiv 1. HIV infection and AIDS HIV infection and AIDS - NICE CKS Clinical Knowledge Summaries Share HIV infection and AIDS - Summary The Human Immunodeficiency Virus ( HIV ) is a retrovirus that preferentially infects and destroys cells of the immune system, in particular the CD4 cells (a class of T lymphocyte, also known as T helper cells). There are 2 main types of HIV : HIV -1 (the predominant type in the UK) is highly virulent and is found (...) Management in Australia has developed specific clinical guidance on the topic of when to start antiretroviral therapy in people with HIV . Key considerations concerning the issue 2011 9. Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection ( HIV /TBL) Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection ( HIV /TBL) - Full Text View - ClinicalTrials.gov A service of the U.S. National Institutes

2018 Trip Latest and Greatest

162. Biomedical and Behavioral Outcomes of Keep It Up!: An eHealth HIV Prevention Program RCT Full Text available with Trip Pro

Biomedical and Behavioral Outcomes of Keep It Up!: An eHealth HIV Prevention Program RCT HIV diagnoses among young men who have sex with men are increasing, but few effective HIV prevention interventions exist for this population. An RCT was conducted of the online Keep It Up! intervention to determine if it significantly reduced condomless anal sex and sexually transmitted infections compared with an HIV knowledge condition.From May 2013 to March 2017, a total of 901 participants were enrolled (...) in a double-blinded RCT of Keep It Up! with 1-year follow-up. After completing baseline surveys and sexually transmitted infection testing, participants were randomized by an eHealth platform to the intervention or control condition.HIV-negative men who have sex with men reporting condomless anal sex, aged 18-29 years, were recruited through advertising and from HIV testing sites and outreach in Atlanta, Georgia; Chicago, Illinois; and New York, New York.Multimedia was used to address HIV knowledge

2018 EvidenceUpdates

163. Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 - GOV.UK GOV.UK uses cookies to make the site simpler. Search Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 New pharmacokinetic data show (...) mean exposure of darunavir (brand name Prezista) boosted with cobicistat (available in combination in Rezolsta▼, Symtuza▼) to be lower during the second and third trimesters of pregnancy than during 6–12 weeks postpartum. Low darunavir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child. Published 17 July 2018 From: Therapeutic area: , , , Contents Advice for healthcare professionals: pharmacokinetic data show low

2018 MHRA Drug Safety Update

164. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance

is underpinned by two guiding principles: promoting human rights and promoting gender equality. Source: Consolidated guideline on sexual and reproductive health and rights of women living with HIV (3).Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV 6 Fig. 1. Example of an algorithm for programmatic implementation of DTG a TLD (fixed-dose combination of TDF + 3TC + DTG) could be considered (...) and the proportion of HIV-uninfected infants that would potentially start treatment unnecessarily. Note that the cycle threshold values vary by the assay used and cannot be directly applied between technologies or assays. Further, additional considerations may be necessary for countries using plasma as a sample type for infant testing rather than whole blood or dried blood spots, since the latter sample types typically capture and amplify intracellular nucleic acids that may increase the detected levels of virus

2018 World Health Organisation HIV Guidelines

165. Correlates of Not Using Antiretroviral Therapy Among Transwomen Living with HIV: The Unique Role of Personal Competence Full Text available with Trip Pro

Correlates of Not Using Antiretroviral Therapy Among Transwomen Living with HIV: The Unique Role of Personal Competence Purpose: This study tested three psychosocial measures for their potential to serve as counseling goals for promoting ART to transgender women living with HIV (TWLH). Methods: Among 69 TWLH, 17.4% were not taking ART; these volunteers were compared to the remainder using multivariate regression analyses. Results: Only one psychosocial measure achieved significance: Personal

2018 Transgender health

166. Bictegravir / emtricitabine / tenofovir alafenamide / fumarate (Biktarvy) - HIV Infections

substance: Bictegravir / Emtricitabine / Tenofovir Alafenamide International Non-proprietary Name/Common Name: Bictegravir / Emtricitabine / Tenofovir Alafenamide Pharmaco-therapeutic group (ATC Code): Direct acting antivirals, antivirals for treatment of HIV infections, combinations (J05AR) Therapeutic indication(s): Biktarvy is indicated for the treatment of adults infected with human immunodeficiency virus 1 (HIV 1) without present or past evidence of viral resistance to the integrase inhibitor class (...) Practice GEN elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (coformulated; Genvoya®) GI gastrointestinal GLSM geometric least-squares mean GS-9883 bictegravir HBeAb hepatitis B e antibody HBeAg hepatitis B e antigen HBsAb hepatitis B surface antibody HBsAg hepatitis B surface antigen HBV hepatitis B virus HCV hepatitis C virus HDPE High Density Polyethylene HIV human immunodeficiency virus HIV-1 human immunodeficiency virus type 1 HLA human leukocyte antigen HPLC High performance liquid

2018 European Medicines Agency - EPARs

167. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. Full Text available with Trip Pro

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. Antiretroviral therapy (ART) is the cornerstone of prevention and management of HIV infection.To evaluate new data and treatments and incorporate this information into updated recommendations for initiating therapy, monitoring individuals starting therapy, changing regimens, and preventing HIV infection for individuals at risk.New evidence (...) collected since the International Antiviral Society-USA 2016 recommendations via monthly PubMed and EMBASE literature searches up to April 2018; data presented at peer-reviewed scientific conferences. A volunteer panel of experts in HIV research and patient care considered these data and updated previous recommendations.ART is recommended for virtually all HIV-infected individuals, as soon as possible after HIV diagnosis. Immediate initiation (eg, rapid start), if clinically appropriate, requires

2018 JAMA

168. HIV. (Abstract)

HIV. The benefits of combination antiretroviral therapy (cART) for HIV replication and transmission control have led to its universal recommendation. Many people living with HIV are, however, still undiagnosed or diagnosed late, especially in sub-Saharan Africa, where the HIV disease burden is highest. Further expansion in HIV treatment options, incorporating women-centred approaches, is essential to make individualised care a reality. With a longer life expectancy than before, people living (...) with HIV are at an increased risk of developing non-AIDS comorbidities, such as cardiovascular diseases and cancers. Antiretroviral strategies are evolving towards a decrease in drug burden, and some two-drug combinations have proven efficacy for maintenance therapy. Investigational immune checkpoint inhibitors and broadly neutralising antibodies with effector functions have energised the HIV cure research field as the search for an effective vaccine continues. In this Seminar, we review advances

2018 Lancet

169. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Full Text available with Trip Pro

a parallel study in rhesus monkeys (NHP 13-19) to assess the immunogenicity and protective efficacy of these vaccine regimens against a series of six repetitive, heterologous, intrarectal challenges with a rhesus peripheral blood mononuclear cell-derived challenge stock of simian-human immunodeficiency virus (SHIV-SF162P3). The APPROACH trial is registered with ClinicalTrials.gov, number NCT02315703.Between Feb 24, 2015, and Oct 16, 2015, we randomly assigned 393 participants to receive at least one dose (...) vaccine candidates in parallel studies in humans and rhesus monkeys to define the optimal vaccine regimen to advance into clinical efficacy trials.We conducted a multicentre, randomised, double-blind, placebo-controlled phase 1/2a trial (APPROACH). Participants were recruited from 12 clinics in east Africa, South Africa, Thailand, and the USA. We included healthy, HIV-1-uninfected participants (aged 18-50 years) who were considered at low risk for HIV-1 infection. We randomly assigned participants

2018 Lancet Controlled trial quality: predicted high

170. The global response and unmet actions for HIV and sex workers. Full Text available with Trip Pro

on HIV and antiretroviral therapy (ART) coverage are scarce, particularly among transgender women. Sustained coverage of treatment is markedly uneven and challenged by lack of progress on stigma and criminalisation, and sustained human rights violations. Although important progress has been made in biomedical interventions with pre-exposure prophylaxis and early ART feasibility and demonstration projects, limited coverage and retention suggest that sustained investment in community and structural (...) to support community and structural interventions, is urgently needed to reverse the HIV trajectory and ensure health and human rights for all sex workers.Copyright © 2018 Elsevier Ltd. All rights reserved.

2018 Lancet

171. Violence, abuse and discrimination: key factors militating against control of HIV/AIDS among the LGBTI sector Full Text available with Trip Pro

Violence, abuse and discrimination: key factors militating against control of HIV/AIDS among the LGBTI sector The Lesbian, Gay, Bisexual, Transgender and Intersex (LGBTI) South Africans continue to face considerable challenges, including societal stigma, homophobic violence (particularly corrective rape), and high rates of sexually transmitted diseases and infections (particularly Human Immunodeficiency Virus (HIV)/AIDS) even when discrimination based on sexual orientation was outlawed by South (...) African's post-apartheid constitution. This study was conducted to ascertain violence, abuse and discrimination against the LGBTI sector as key factors that hinder the smooth implementation of HIV/AIDS programme among sexually minority (LGBTI) group in Walter Sisulu University, South Africa. The self-structured questionnaire was used to collect data. The study involved 3048 purposively selected participants (1285 male and 1763 female) aged 17-38 years. About 70.5% of the participants witnessed physical

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

172. Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial. Full Text available with Trip Pro

Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial. Current diagnostics for HIV-associated tuberculosis are suboptimal, with missed diagnoses contributing to high hospital mortality and approximately 374 000 annual HIV-positive deaths globally. Urine-based assays have a good diagnostic yield; therefore, we aimed to assess whether urine-based screening (...) in HIV-positive inpatients for tuberculosis improved outcomes.We did a pragmatic, multicentre, double-blind, randomised controlled trial in two hospitals in Malawi and South Africa. We included HIV-positive medical inpatients aged 18 years or more who were not taking tuberculosis treatment. We randomly assigned patients (1:1), using a computer-generated list of random block size stratified by site, to either the standard-of-care or the intervention screening group, irrespective of symptoms

2018 Lancet Controlled trial quality: predicted high

173. Performance of verbal autopsy methods in estimating HIV-associated mortality among adults in South Africa Full Text available with Trip Pro

Performance of verbal autopsy methods in estimating HIV-associated mortality among adults in South Africa Verbal autopsy (VA) can be integrated into civil registration and vital statistics systems, but its accuracy in determining HIV-associated causes of death (CoD) is uncertain. We assessed the sensitivity and specificity of VA questions in determining HIV status and antiretroviral therapy (ART) initiation and compared HIV-associated mortality fractions assigned by different VA interpretation (...) methods.Using the WHO 2012 instrument with added ART questions, VA was conducted for deaths among adults with known HIV status (356 HIV positive and 103 HIV negative) in South Africa. CoD were assigned using physician-certified VA (PCVA) and computer-coded VA (CCVA) methods and compared with documented HIV status.The sensitivity of VA questions in detecting HIV status and ART initiation was 84.3% (95% CI 80 to 88) and 91.0% (95% CI 86 to 95); 283/356 (79.5%) HIV-positive individuals were assigned HIV

2018 BMJ global health

174. Dolutegravir (HIV infection) - Addendum to commission A17-11

Dolutegravir (HIV infection) - Addendum to commission A17-11 1 Translation of addendum A17-37 Dolutegravir (HIV-Infektion) – Addendum zum Auftrag A17-11 (Version 1.0; Status: 30 August 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 30 August 2017 1.0 Commission: A17-37 Version: Status: IQWiG Reports – Commission No. A17-37 Dolutegravir (HIV (...) infection) – Addendum to Commission A17-11 1 Addendum A17-37 Version 1.0 Dolutegravir – Addendum to Commission A17-11 30 August 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dolutegravir (HIV infection) – Addendum to Commission A17-11 Commissioning agency: Federal Joint Committee Commission awarded on: 10 August 2017 Internal Commission No.: A17-37 Address of publisher: Institut für Qualität

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

175. HIV and infant feeding in emergencies: operational guidance

contributions to the process.vi HIV AND INFANT FEEDING IN EMERGENCIES: OPERATIONAL GUIDANCE Abbreviations and acronyms AIDS acquired immunodeficiency syndrome ANC antenatal care ART antiretroviral therapy ARV antiretroviral drug AZT zidovudine BMS breast-milk substitute(s) ENN Emergency Nutrition Network HIV human immunodeficiency virus IFE infant and young child feeding in emergencies IYCF infant and young child feeding MTCT mother-to-child transmission of HIV NGO nongovernmental organization NVP (...) : the infant receives only breast milk without any other liquids or solids, not even water, except for oral rehydration solution or drops or syrups of vitamins, minerals or medicines. Generalized HIV epidemic: HIV is firmly established in the general population. Numerical proxy: HIV prevalence is consistently over 1% among pregnant women. Most generalized HIV epidemics are mixed in nature, where certain (key) subpopulations are disproportionately affected. HIV: the human immunodeficiency virus

2018 World Health Organisation Guidelines

176. Raltegravir (Isentress) - human immunodeficiency virus in neonates

Raltegravir (Isentress) - human immunodeficiency virus in neonates Published 9 July 2018 Statement of Advice: raltegravir 100mg granules for oral suspension (Isentress ® ) SMC2101 Merck Sharp & Dohme Limited 8 June 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation raltegravir (Isentress ® ) is not recommended for use within NHSScotland. Indication under review: in combination with other anti-retroviral medicinal products in the treatment of human (...) immunodeficiency virus in neonates. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining

2018 Scottish Medicines Consortium

177. New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir

in the EU will be sent a dear healthcare professional letter concerning these recommendations. More about the medicine Dolutegravir is an integrase inhibitor. This means that it blocks an enzyme called integrase that is needed by the HIV virus to make new copies of itself in the body. When it is given with other medicines, it helps to prevent the spread of HIV and keep the amount of the virus in the blood at a low level. Dolutegravir does not cure HIV infection or AIDS, but it may hold off damage (...) New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir | European Medicines Agency Search Search Menu New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir Press release 18/05/2018 While EMA review is ongoing, dolutegravir should not be used in women seeking to become pregnant The European Medicines Agency (EMA

2018 European Medicines Agency - EPARs

178. Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study. Full Text available with Trip Pro

Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study. Evidence regarding potential adverse neuropsychiatric effects of efavirenz is conflicting, and data from sub-Saharan Africa, where 70% of persons living with HIV (PLHIV) reside and efavirenz is used as first-line therapy, are limited.To estimate associations between efavirenz use and depression and suicidal ideation among PLHIV in Uganda.Prospective

2018 Annals of Internal Medicine

179. The rise and fall of mortality inequality in South Africa in the HIV era Full Text available with Trip Pro

The rise and fall of mortality inequality in South Africa in the HIV era Post-apartheid South Africa has seen an unprecedented rise and fall of mortality in less than two decades as a result of the HIV/AIDS epidemic and the subsequent rollout of free antiretroviral therapy (ART). Since the incidence of both was not equal for rich and poor, it is likely to also have affected disparities in health and survival chances by income. We use large nationwide surveys for 2001, 2007 and 2011 to obtain (...) the 2001-2011 period. The analysis of age-sex-specific mortality rates shows that it was in particular for adults aged 18-59 years that mortality and absolute inequality increased substantially between 2001 and 2006, followed by a rapid drop thereafter. These trends were far more pronounced for males than females. This means that the HIV/AIDS epidemic has taken a serious death toll, which was concentrated disproportionately among the poorest segments of the population and especially affected (older

2018 SSM - population health

180. NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation Full Text available with Trip Pro

NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation 29921650 2019 03 15 2473-9537 2 12 2018 06 26 Blood advances Blood Adv NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. 1412-1416 10.1182/bloodadvances.2018016329 Hogan Louise E LE Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA

2018 Blood advances